BlueWillow Biologics® is a clinical-stage, privately-held biopharmaceutical company focused on developing and commercializing topical antiseptic and anti-infective products and intranasal vaccines using its patented nanotechnology platform. The platform employs novel oil-in-water nano-droplets for products administered to the skin and nose. The company was founded as a spin-off from the University of Michigan, and was initially focused on developing nano-scale dermatology applications. Based on promising research generated under several Gates Foundation, NIH and DOD contracts, BlueWillow technology has been advanced significantly in recent years yielding several therapies in development. BlueWillow lead NanoBio® Protect product is an alcohol-free, nasal antiseptic that has been shown to kill 99.99% of germs in lab tests. The FDA Over-the-Counter (OTC) product is applied by thoroughly swabbing the skin inside of each nostril and is recommended for use to help reduce germs on the skin that can cause infection. NanoBio® Protect is non-irritating, fragrance-free and leaves no residue after application. Other topical NanoBio® products are currently being developed for wounds and other skin ailments.